Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.

Trial Details

NCT ID

NCT06514508

Phase

PHASE3

Sponsor

Guangzhou Gloria Biosciences Co., Ltd.

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Motixafortide+G-CSF
Placebo+G-CSF

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723
Harbin, Hei Longjiang, China|45.75,126.65

Key Eligibility Criteria

(Limit: 15,000 characters)
Patients must have a signed study informed consent prior to entering the study.
Patients must be between the ages of 18 and 78 years.
Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →